Watch CNBC's full interview with Novo Nordisk CEO Mike Doustdar

Core Insights - The company is undergoing a strategic shift towards a more aggressive approach in addressing diabetes and obesity, with a focus on mergers and acquisitions (M&A) to enhance its capabilities and pipeline [1][2][3] - There is a commitment to not only build but also acquire assets that can address the significant unmet needs in diabetes and obesity, indicating a sustained M&A strategy [2][3] - The company emphasizes the importance of affordability and access to medications, particularly in the U.S. market, where a large number of individuals suffering from obesity remain untreated [6][7][8] M&A Strategy - The company has spent approximately $7 billion on M&A to accelerate its pipeline and address the needs of the diabetes and obesity markets [1][2] - Future M&A activities are expected to continue as the company seeks to acquire complementary assets that align with its core focus [2][3] - The company is confident in its pipeline and does not view M&A as a sign of weakness but rather as a means to enhance its offerings [3][4] Market Dynamics - The U.S. obesity market is experiencing challenges, with a noted decline in demand, prompting the company to negotiate lower prices and improve direct-to-consumer strategies [5][6] - There are 100 million individuals suffering from obesity in the U.S., with only 34 million currently receiving treatment, highlighting a significant opportunity for market expansion [6][7] - The company acknowledges that reducing prices may require a substantial increase in volume to maintain profitability, but believes there is ample volume to tap into [8][9] Product Development - The company is excited about the potential of a new oral medication for obesity that matches the efficacy of injectable options, which could significantly impact the market [14][15] - Research into the effects of its products on other conditions, such as Alzheimer's, is ongoing, with the potential for significant breakthroughs [16][15] Restructuring and Investments - A major restructuring plan has been implemented, resulting in the reduction of 900 jobs and expected savings of 8 billion kronas, with 95% of the plan already completed [17][18] - The company has invested over $24 billion in the U.S., expanding its operations and focusing on being a good corporate citizen while also maintaining investments in Europe [24][25] Strategic Focus - The primary focus is on ensuring that medications reach those in need while also building and complementing the existing pipeline through strategic partnerships and acquisitions [26][27] - The company aims to responsibly make anti-obesity drugs available while ensuring that they are targeted towards those who genuinely need them [27][28]